HER-2 Positive Breast Cancer Clinical Trials

33 clinical trials for HER-2 Positive Breast Cancer across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• HER2+ CNS Surveillance — RECRUITING · NA
• A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer — RECRUITING · PHASE2
• Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer — RECRUITING · PHASE2
• Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease — RECRUITING
• Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial) — NOT_YET_RECRUITING · PHASE2
• T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA — ACTIVE_NOT_RECRUITING · PHASE2
• A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) — ACTIVE_NOT_RECRUITING · PHASE2
• Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer — NOT_YET_RECRUITING · NA
• Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1 — COMPLETED · PHASE2
• Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer — COMPLETED · PHASE3
• A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer — COMPLETED · PHASE2
• A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer — COMPLETED · PHASE2
• Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer — COMPLETED · PHASE2
• Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer — COMPLETED · PHASE1
• A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer — OTHER · PHASE3
• Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer — TERMINATED · PHASE1
• A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer — COMPLETED · PHASE1
• PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study — OTHER
• Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) — COMPLETED · PHASE3
• Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer — TERMINATED · PHASE2
• Strain Imaging in Breast Cancer Patients Receiving Trastuzumab — COMPLETED
• A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases — COMPLETED · PHASE2
• AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer — WITHDRAWN · PHASE1
• Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer — WITHDRAWN · NA
• Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer — COMPLETED · PHASE2
• A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer — TERMINATED · PHASE1
• An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer — COMPLETED · PHASE2
• Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer — TERMINATED · PHASE1
• Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab — COMPLETED · PHASE2
• Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer — OTHER · PHASE2
• Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years — COMPLETED

Refine this search